FLGR-242 / Follistatin: Everything You Need To Know Before You Buy

There's a modified phallostatin product called FLGR242 that's getting a lot of attention right now, and the headline claim attached to it is up to a pound and a half of skeletal muscle per week, which would put it well past anything testosterone does on its own.

Two things are true at the same time here. The biology of myostatin inhibition is real and has decades of published work behind it, and this specific molecule has never been through a human clinical trial of any kind.

The person making the largest claims about it also co-owns the company that manufactures and sells it. So before you spend money, you should understand the pathway well enough to judge the product yourself.

Start with the whole chain, because if you don't understand the pathway, nothing else about the compound is going to make sense.

Your body produces a protein called myostatin, also known as GDF-8, and it is made by your muscle and acts back on your muscle as a brake on growth. It signals through a receptor called actribe on the surface of your muscle cells, and when that signal gets through, it activates a pathway called SMOD2-3 that suppresses your body's ability to build muscle protein.

That suppression happens in two places at once. The signaling proteins move into the nucleus and change which genes get read, and at the same time the pathway pulls down the growth signaling that testosterone, food, and training all feed into, so you get less protein synthesis from the same inputs.

Walsh and Celeste described a second job for myostatin in 2005, which is holding your satellite cells quiet. Satellite cells are the stem cells sitting alongside your muscle fibers that donate new nuclei when a fiber needs to grow, and myostatin keeps them parked.

Follistatin is your body's natural way of releasing that brake. It binds to myostatin and pulls it out of circulation before it can ever reach those receptors, which works the way a sponge works on a spill, soaking up the signal so it never lands.

The pathway is druggable at more than one point, which tells you the mechanism is solid. El Shafey and colleagues showed in 2016 that short peptides derived from decorin, a protein in your connective tissue, can block myostatin from turning on that same SMOD2-3 signaling in cultured muscle cells.

And the human evidence is not theoretical. There was a case published in the New England Journal of Medicine back in 2004 where a child was born with a genetic mutation that knocked out his myostatin completely, and he was extraordinarily muscular from birth with completely normal organ development.

A large genetic study published in 2026 confirmed that people carrying these types of mutations consistently have more muscle mass, more strength, and less body fat than the general population.

Then there are the gene therapy trials out of Nationwide Children's Hospital, where Mendell and his team injected a virus carrying the follistatin gene directly into the quadriceps of patients with Becker muscular dystrophy and sporadic inclusion body myositis, and reported in Molecular Therapy that those patients improved on how far they could walk in six minutes, not simply on how big their muscles looked on imaging.

In primates, the same approach produced muscles that were 15% larger and 78% stronger, and those results held through 15 months of follow-up.

So the pathway is backed by published genetics, gene therapy trials, and billions of dollars of pharmaceutical research. The question is whether FLGR242 specifically can deliver on it.

Now, FLGR242 is a modified version of follistatin 344, and it has two changes from the natural protein.

The first is called the FSII variant, and it comes out of published peer reviewed work. The researchers removed the part of follistatin that binds to a protein called activen while keeping the part that binds to myostatin.

That reduced activen binding by about 250-fold.

This gets marketed as a safety feature, and there is a real reason for that, because activen is involved in reproductive signaling, inflammation, wound repair, and a long list of processes that have nothing to do with muscle, so mopping all of it up with natural follistatin creates side effects you didn't ask for.

The trade-off is where it gets complicated. Regeneron just ran a 999 patient phase II trial called COURAGE where they tested myostatin blockade alone versus myostatin plus activen blockade together, and the results were striking.

Adding activen blockade on top of myostatin blockade nearly doubled the amount of lean mass that patients preserved and added 34% more fat loss.

Read that number again in terms of the product you're being sold. Activen blockade appears to account for roughly half of what makes this pathway work in a human body, and the flagship modification in FLGR242 is the removal of activen binding.

Now, that same combination arm had a 28.3% discontinuation rate and more severe side effects. So the modification does buy you something real on the safety side, and it costs you something real on the effect side, and you should walk in knowing which side of that trade you're taking.

The reason activen matters so much specifically in humans comes down to a species difference that gets glossed over constantly. In mice, myostatin is the dominant brake, and knocking it out alone produces those double muscled animals you've seen photographs of.

But in humans and primates, activen A circulates at comparable levels to myostatin and actually binds to the same receptors with 20 times higher affinity. Block myostatin and leave activen alone in a human, and half the brake is still engaged.

This is exactly why the pharmaceutical industry moved upstream to the receptor. Lach-Trifilieff and colleagues published work in Molecular and Cellular Biology in 2014 on an antibody that blocks the activin type II receptors directly, and blocking the receptor produced greater hypertrophy than blocking myostatin alone, because nothing that binds there gets through, no matter which ligand it is.

The second modification is an albumin binding construct, a 29 amino acid addition designed to extend the half-life by attaching to albumin in your blood.

Albumin recycles through your system for about 19 days, so the idea is that FLGR242 hitches a ride on that cycle instead of getting filtered out in hours. The principle is validated, and semaglutide uses the same trick.

Semaglutide is a 4 kDa peptide, though, and FLGR242 is a 40 kDa protein, which is ten times the size and behaves completely differently in terms of absorption, distribution, and clearance. Nobody has published pharmacokinetic data showing that the 19 day half-life claim holds for a molecule this size, and there is no published peak concentration, no measured half-life, and no dose response curve in humans.

The patent on that albumin binding technology is held by an individual named Michael Farber rather than by the company selling the product, and no licensing arrangement has been publicly disclosed.

Jay Campbell is the primary person promoting this compound, and he is the co-founder and co-owner of BioLongevity Labs, which manufactures and sells it. He previously published an article on his own website titled Stay Away from Pholestatin 344, where he specifically wrote that mouse myostatin models don't translate well to humans because mice have 3 to 10 times higher myostatin expression than we do.

He reversed that position after developing FLGR242. His site cites 24 scientific references, and every one of them is an animal study or a cell culture study, with none of them examining FLGR242 in a human being.

That earlier article was correct on the science, and it is the same argument I just walked through with activen A. A mouse gets most of its muscle brake from myostatin, so removing it produces a dramatic animal, and a human splits that brake across two signals.

Every major pharmaceutical company has tried to build a myostatin inhibitor, including Wyeth, Pfizer, Roche, Novartis, and Acceleron. Each one reliably increased muscle volume on imaging, and each one failed to produce meaningful improvements in strength or physical function.

So basically the industry has learned that blocking myostatin grows muscle that doesn't necessarily perform better and every company in this space has now pivoted towards obesity and GLP-1 combination therapy instead.

Based on the receptor antibody data, the realistic ceiling for a myostatin focused approach layered on top of TRT looks like one to three kilograms of additional lean mass across three to six months. That is a real effect, and it is nowhere near a pound and a half a week.

Route of delivery is the other thing that separates the trial data from the vial in your fridge. Gene therapy puts a virus inside your muscle cells so those cells manufacture follistatin locally and continuously for months, at the exact site where you want it.

A subcutaneous injection of a 40 kDa protein has 50 to 80 percent bioavailability, spreads across your entire body instead of concentrating in the target muscle, and gets chewed up by enzymes along the way.

The dose math is still worth running. Five milligrams gets you to about 75 times your endogenous levels but the mouse study that showed meaningful muscle gains required an alimetric dose equivalent to about 360 milligrams in a human and stability is a concern.

Published data shows 22 percent bioactivity loss within 72 hours at refrigerator temperature and 15 to 30 percent per freestyle cycle, which means the protein degrades in ordinary handling conditions, and a product that lost a third of its activity in shipping will produce exactly the same result as a product that never contained anything.

The question that's left is what people who are actually injecting phallostatin are experiencing and that data looks very different from the claims being made.

Forum logs going back more than a decade are dominated by people reporting that nothing happened. The most dramatic report was a user who gained 17 pounds in three weeks from one batch that could never replicate it from any vendor including the same one.

An analytical study of black market follistatin found the protein present in only 53 percent of products tested, with the rest containing unrelated peptides or nothing at all, which explains a lot of the noise in those logs.

There are also no clean data points, because every user log involves testosterone, growth hormone, or anabolic steroids running at the same time. Campbell's own eight-week run on FLGR 242 showed roughly two pounds of weight change while running TRT growth hormone and other compounds simultaneously.

On safety, the cancer concern is specific rather than general. The published literature suggests follistatin promotes the growth of tumors that already exist without appearing to initiate new ones.

That distinction matters because about 15 to 20 percent of men in their 40s carry occult tumors they don't know about, predominantly indolent prostate cancer, so screening before you use anything that removes a growth brake is worth the appointment.

Myostatin deficient animals also show tendons that don't scale with the muscle they now have to move, which is a structural mismatch you'd feel as a connective tissue injury rather than a lab value, along with cardiac changes whose long term meaning is still unclear.

And cessation data from the closest mouse analog shows that gains fully reverse within about 145 days of stopping because myostatin inhibition grows muscle by expanding existing cell domains not by adding new muscle nuclei the way resistance training.

Each nucleus in a muscle fiber can only supply protein for so much surrounding tissue, and training recruits satellite cells to donate additional nuclei, which raises the ceiling permanently and is why detrained lifters come back fast. Myostatin blockade stretches the existing nuclei to cover more territory, and when the drug leaves, the territory shrinks back to what those nuclei can hold.

Which is why exercise is not optional with any of this. In the inclusion body myositis gene therapy trial patients who exercised gained 58 to 153 meters on their walking test while patients on the same treatment who didn't exercise only gained 5 to 23 meters.

Same drug, same dose, same disease, and the difference between a large functional gain and a rounding error was whether the patient trained.

Whether FLGR 242 specifically delivers on the claims being made about it is something that nobody can answer right now because the data just doesn't exist. No human pharmacokinetics, no controlled efficacy trial, no independent assay of what's in the vial, and no long term safety follow up.

What you're being asked to buy is a validated pathway wrapped around an unvalidated molecule, and those are two separate purchases. The pathway will still be there in five years when somebody finally runs the trial, and your tendons, your prostate, and your money only get spent once.

References:

Lach-Trifilieff E, Minetti GC, Sheppard K et al.. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014. https://pubmed.ncbi.nlm.nih.gov/24298022/

Walsh FS, Celeste AJ. Myostatin: a modulator of skeletal-muscle stem cells. Biochem Soc Trans. 2005. https://pubmed.ncbi.nlm.nih.gov/16246158/

El Shafey N, Guesnon M, Simon F et al.. Inhibition of the myostatin/Smad signaling pathway by short decorin-derived peptides. Exp Cell Res. 2016. https://pubmed.ncbi.nlm.nih.gov/26844629/

Mendell JR, Sahenk Z, Al-Zaidy S et al.. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017. https://pubmed.ncbi.nlm.nih.gov/28279643/

Mendell JR, Rodino-Klapac L, Sahenk Z et al.. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett. 2012. https://pubmed.ncbi.nlm.nih.gov/22609847/